U.S. Markets open in 6 hrs 44 mins
  • S&P Futures

    4,704.00
    +2.50 (+0.05%)
     
  • Dow Futures

    35,830.00
    +19.00 (+0.05%)
     
  • Nasdaq Futures

    16,494.75
    +13.50 (+0.08%)
     
  • Russell 2000 Futures

    2,365.40
    +1.20 (+0.05%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    56,329.90
    -1,212.19 (-2.11%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Notwithstanding the ESMO conference generating some huge moves in some stocks, last week turned out to be a muted one for biotechs.

A few FDA approvals came through, with Puma Biotechnology Inc (NASDAQ: PBYI) getting a label expansion for its breast cancer drug Nerlynx and Novartis AG (NYSE: NVS)'s Entresto, a combo therapy, given the go ahead for pediatric heart failure.

Here are the key biotech catalysts for the unfolding week.

Conferences

  • European Huntington Association Conference: Oct. 4–6 in Bucharest, Romania

  • Experts Gather on Cardiovascular Disorders and Cardiology Research: Oct. 7-8 in Paris, France

  • 5th Annual Congress on Infectious Diseases: Oct. 7-8 in Frankfurt, Germany

  • 9th International Conference on Neurological Disorders & Stroke: Oct. 7-8 in Dublin, Ireland

  • Chardan 3rd Annual Genetic Medicines Conference: Oct. 7-8 in New York City

  • Jefferies Gene Therapy/Editing Summit: Oct. 8 in New York City

  • 37th World Cancer Conference: Oct. 9-10 in Dublin

  • 28th European Academy of Dermatology and Venereology, or EADV, Congress: Oct. 9-13, in Madrid, Spain

  • Ophthalmology Innovation Summit: Oct. 10 in San Francisco, California

  • American Academy of Ophthalmology, or AAO: Oct. 12-15, in San Francisco

Related Link: Sell-Side Positive On Johnson & Johnson's Unexpected Ohio Opioid Settlement

PDUFA Dates

The FDA is scheduled to rule on Pfenex Inc (NYSE: PFNX)'s PF708, a therapeutic equivalent of Eli Lilly And Co (NYSE: LLY)'s Forteo, which was approved in 2002 to treat osteoporosis in men and menopausal women, who are at high risk of having a fracture. The PDUFA date is set for Monday.

The regulatory body will issue its verdict Tuesday on Clinuvel Pharmaceuticals Ltd (OTC: CLVLY)'s NDA for Scenesse, which is being evaluated as a preventative treatment for phototoxicity and anaphylactoid reactions in adult patients with erythropoietic protoporphyria.

Clinical Trial Readouts 28th EADV Congress Presentations

Akari Therapeutics PLC (NASDAQ: AKTX) – Additional Phase 2 data for Coversin in bullous pemphigoid (Thursday)

Concert Pharmaceuticals Inc (NASDAQ: CNCE) – Phase 2 data for CTP-543 in alopecia areata (Saturday)

AAO 2019 Presentations

Adverum Biotechnologies Inc (NASDAQ: ADVM) – Additional Phase 1 data for ADVM-022 in wet age-related macular degeneration Friday)

Regenxbio Inc (NASDAQ: RGNX) – Phase 1/2a data for RGX-314 in wet age-related macular degeneration (Friday)

IPOs

BioNTech, a German biotech developing individualized monotherapies for cancer, is planning a 13.2-million share IPO, which is estimated to be priced between $18 and $20. The company proposes to list shares on the Nasdaq under the ticker symbol "BNTX."

Vir Biotechnology, a biotech developing immunologic therapies for infectious diseases, is seeking to list shares on the Nasdaq through an IPO of 7.14 million shares in the price range of $20 to $22 per share. Shares will be listed under the ticker symbol "VIR."

IPO Quiet Period Expiry

Satsuma Pharmaceuticals Inc (NASDAQ: STSA)
SpringWorks Therapeutics Inc (NASDAQ: SWTX)
10X Genomics Inc (NASDAQ: TXG)

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.